ClinicalTrials.gg

Program

VRN110755

A development code.

Its studies are mostly in Carcinoma, Non-Small-Cell Lung, led by Voronoi.

Furthest: phase 2, since Jul 1, 20262 company-led studies, 1 open or runningNext primary completion: Jan 1, 2029 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Voronoi21 open or runningphase 2since Jul 1, 2026Jul 24, 2025Jan 1, 2029phase 2 · NCT07699328

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jul 24, 2025First study: phase 1 study in HealthyFirst studyNCT07141381 · 25 enrolled · Australia
  2. Jul 1, 2026Phase 2 study in Carcinoma, Non-Small-Cell LungPhase 2 reachedNCT07699328 · 315 planned · Australia, Canada, France and more

Ahead

  1. Jan 1, 2029Primary completion: phase 2 study in Carcinoma, Non-Small-Cell LungNCT07699328

TargetBeta

EGFR →read by rule
“This first-in-human, Phase 1/2, multicenter, open-label, non-randomized study evaluates the safety, tolerability, pharmacokinetics, pharmacodynamics, and antitumor activity of VRN110755, a highly selective oral epidermal growth factor receptor (EGFR) inhibitor, in patients with EGFR-mutant non-sm…”study text, by rule · the study

Other programs on EGFR

ProgramCompanyFurthest phaseStudies
izalontamab brengitecanSichuan Biokin Pharmaceuticalphase 355
pimurutamabFosun Pharmaphase 317
Anti-EGFR Antibody-drug Conjugate CPO301CSPC Pharmaceutical Groupphase 316
sunvozertinibruleDizal Pharmaceuticalsphase 312
becotatugCSPC Pharmaceutical Groupphase 311
andamertinibruleavistone-biotechnology-co-ltdphase 310
becotatug vedotinrulelepu-biopharma-co-ltdphase 310
sevabertinibruleBayerphase 38
HS-10504Hansoh Pharmaceutical Groupphase 37
petosemtamabruleGenmabphase 36
bafisontamabruleshanghai-epimab-biotherapeutics-co-ltdphase 35
zipalertinibruleOtsukaphase 34

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07699328Carcinoma, Non-Small-Cell Lung · Australia, Canada, France and more2RecruitingJan 1, 2029315
NCT07141381Healthy · Australia1CompletedDec 17, 202525

How it is read

Names in the registry

  • “VRN110755”, 2 entries

Codes read as this program: VRN110755.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.